Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial

This publication has 15 references indexed in Scilit:

• ENHANCE: Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis*
  Pediatric Critical Care Medicine, 2006
• International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*
  Pediatric Critical Care Medicine, 2005
• Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
  Journal of Thrombosis and Haemostasis, 2004
• Fresh Whole Blood versus Reconstituted Blood for Pump Priming in Heart Surgery in Infants
  New England Journal of Medicine, 2004
• Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children With Severe Sepsis
  Pediatrics, 2004
• SEPTIC STOCK
  Pediatric Clinics of North America, 2001
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001
• Sepsis in neonates and children
  Pediatric Emergency Care, 1997
• ADVANCES IN THE THERAPY FOR SEPSIS IN CHILDREN
  Pediatric Clinics of North America, 1997
• PRISM III
  Critical Care Medicine, 1996